Meet the MET.

MET alterations are the primary driver mutations of 3-4% of non-small cell lung cancers (NSCLC), but they’ve proven notoriously difficult to target. In that sense, the phase 2 VISION trial is a game-changer. Among 99 patients with NSCLC with a MET exon 14 skipping mutation confirmed on liquid and/or tissue biopsy, almost half achieved a response by RECIST criteria and two-thirds a deep (14%) or complete (53%) molecular response to the highly-selective MET-inhibitor tepotinib. | Paik, N Eng J Med 2020